Marc Carrier: Proud to Share the Results of the WAVe Study
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”Proud to share the results of the WAVe Study published in AjHematology
In this Canadian multicenter collaboration across six academic centers, we evaluated weight-adjusted dalteparin dosing (up to 33,000 IU/day) in patients with cancer-associated thrombosis weighing >90 kg.
Despite early study termination due to recruitment challenges — following the rapid uptake of DOACs for VTE and updated ISTH guidance removing the upper weight limit for DOAC use — our findings remain clinically relevant:
- Major bleeding: 5.3% at 30 days
- Recurrent VTE: 1.2% at 30 days
- No significant drug accumulation (based on anti-Xa levels)
These results suggest that weight-adjusted LMWH remains a safe and effective option for selected patients with cancer and obesity, particularly those at higher bleeding risk or with contraindications to DOACs.”
Read the full article here.
Article: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier

Stay updated on all scientific advances with Hemostasis Today.
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management